SLRX (Salarius Pharmaceuticals Inc) סך כל נכסי החברה

Salarius Pharmaceuticals (SLRX) is currently in the clinical trial stage without a stable cash flow, and its liquidity stands at 4.97. The company is mitigating risks by developing epigenetic therapies to combat rare tumors. This chart of the aggregate asset market price confirms the potential of the business, whose patents for enzyme inhibitors will ensure a prolonged period of exclusivity and sustained demand from medical professionals.

Since this metric is calculated inversely via ROA, it reacts sharply to operating profit volatility, measuring the total volume of resources and liabilities to assess financial stability. In the case of Salarius Pharmaceuticals (SLRX), this reflects the ability to maintain complex chemical formula supply chains and the diversification of research bases, which is confirmed through the monitoring of total assets (via ROA).